Pub Date : 2020-10-16DOI: 10.23736/S0392-0488.20.06664-X
F. Bardazzi, L. Sacchelli, R. Balestri, F. Filippi, A. Patrizi, Ivano Iozzo, C. Loi
{"title":"Recalcitrant oral involvement in pemphigus vulgaris successfully treated with platelet-rich plasma.","authors":"F. Bardazzi, L. Sacchelli, R. Balestri, F. Filippi, A. Patrizi, Ivano Iozzo, C. Loi","doi":"10.23736/S0392-0488.20.06664-X","DOIUrl":"https://doi.org/10.23736/S0392-0488.20.06664-X","url":null,"abstract":"","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2020-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72724057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-16DOI: 10.23736/S0392-0488.20.06675-4
D. Didona, G. Di Zenzo, P. Joly
Originally described by Anhalt as paraneoplastic pemphigus in 1990, paraneoplastic autoimmune multiorgan syndrome (PAMS) is a potentially lethal blistering disease, characterized by polymorphous clinical features, including mucocutaneous erosions, blisters, lichenoid papules, and erythema. Several autoantibodies have been detected in serum of PAMS patients, including anti-plakins, anti-alpha-2-macroglobulin like 1, and anti-desmogleins autoantibodies. The mortality rate of PAMS is up to 50%. This is due on the one hand to the poor response to treatments and on the other hand to the delay in the diagnosis and to the prognosis of the underlying neoplasia.
{"title":"Paraneoplastic autoimmune multiorgan syndrome (PAMS).","authors":"D. Didona, G. Di Zenzo, P. Joly","doi":"10.23736/S0392-0488.20.06675-4","DOIUrl":"https://doi.org/10.23736/S0392-0488.20.06675-4","url":null,"abstract":"Originally described by Anhalt as paraneoplastic pemphigus in 1990, paraneoplastic autoimmune multiorgan syndrome (PAMS) is a potentially lethal blistering disease, characterized by polymorphous clinical features, including mucocutaneous erosions, blisters, lichenoid papules, and erythema. Several autoantibodies have been detected in serum of PAMS patients, including anti-plakins, anti-alpha-2-macroglobulin like 1, and anti-desmogleins autoantibodies. The mortality rate of PAMS is up to 50%. This is due on the one hand to the poor response to treatments and on the other hand to the delay in the diagnosis and to the prognosis of the underlying neoplasia.","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2020-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78486077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-16DOI: 10.23736/S0392-0488.20.06672-9
F. Boggio, E. Guanziroli, Marco Barella, L. Venegoni, E. Berti, S. Ferrero, A. Coggi, R. Gianotti, A. Del Gobbo
BACKGROUND Clear cell morphology has been described in several cutaneous neoplasms either as a specific feature of some entities either as a morphological variant in the spectrum, and these two entities are frequently considered together in the differential diagnosis. METHODS We reviewed our series of cases occurred in our laboratory in order to further quantify the number of cases showing morphological features of tricholemmal differentiation and to investigate other clinical or histological difference. We retrieved 91 cases and, for each of them, all the clinical data regarding age, sex, clinical features, and clinical suspicious were collected, when available. RESULTS The revision of the specimens concluded with a final diagnosis of tricholemmal carcinoma in 15 cases (17%), all the other cases were thus considered as squamous cell carcinoma with clear cell features. No statistically significant correlations were observed with the demografic or clinicopatholagical parameters such as age, sex or dimensions, but morphological revision highlighted a potentially greater "vertical" growth frequently not matched by a concomitant radial one in tricholemmal carcinoma than in squamous tumors. CONCLUSIONS The debate upon the diagnostic distinction of these tumours is still ongoing with authors proposing the tricholemmal carcinoma as a variant of a squamous cell carcinoma rather than a distinct entity. Further studies are needed to confirm our data and to evaluate the reproducibility of this feature.
{"title":"Cutaneous tricholemmal carcinoma: a 15-years single centre experience.","authors":"F. Boggio, E. Guanziroli, Marco Barella, L. Venegoni, E. Berti, S. Ferrero, A. Coggi, R. Gianotti, A. Del Gobbo","doi":"10.23736/S0392-0488.20.06672-9","DOIUrl":"https://doi.org/10.23736/S0392-0488.20.06672-9","url":null,"abstract":"BACKGROUND\u0000Clear cell morphology has been described in several cutaneous neoplasms either as a specific feature of some entities either as a morphological variant in the spectrum, and these two entities are frequently considered together in the differential diagnosis.\u0000\u0000\u0000METHODS\u0000We reviewed our series of cases occurred in our laboratory in order to further quantify the number of cases showing morphological features of tricholemmal differentiation and to investigate other clinical or histological difference. We retrieved 91 cases and, for each of them, all the clinical data regarding age, sex, clinical features, and clinical suspicious were collected, when available.\u0000\u0000\u0000RESULTS\u0000The revision of the specimens concluded with a final diagnosis of tricholemmal carcinoma in 15 cases (17%), all the other cases were thus considered as squamous cell carcinoma with clear cell features. No statistically significant correlations were observed with the demografic or clinicopatholagical parameters such as age, sex or dimensions, but morphological revision highlighted a potentially greater \"vertical\" growth frequently not matched by a concomitant radial one in tricholemmal carcinoma than in squamous tumors.\u0000\u0000\u0000CONCLUSIONS\u0000The debate upon the diagnostic distinction of these tumours is still ongoing with authors proposing the tricholemmal carcinoma as a variant of a squamous cell carcinoma rather than a distinct entity. Further studies are needed to confirm our data and to evaluate the reproducibility of this feature.","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2020-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83805980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-16DOI: 10.23736/S0392-0488.20.06660-2
C. Patruno, G. Fabbrocini, M. D'andrea, S. Dastoli, C. Marasca, M. Napolitano
{"title":"Frequency of allergic contact dermatitis in hidradenitis suppurativa patients.","authors":"C. Patruno, G. Fabbrocini, M. D'andrea, S. Dastoli, C. Marasca, M. Napolitano","doi":"10.23736/S0392-0488.20.06660-2","DOIUrl":"https://doi.org/10.23736/S0392-0488.20.06660-2","url":null,"abstract":"","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2020-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82996646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-16DOI: 10.23736/S0392-0488.20.06671-7
P. Facheris, A. D’Arino, G. Pavia, M. Valenti, G. Guidelli, R. Borroni, A. Costanzo, A. Narcisi
{"title":"Urticarial rash in autoinflammatory syndromes: a report of three cases.","authors":"P. Facheris, A. D’Arino, G. Pavia, M. Valenti, G. Guidelli, R. Borroni, A. Costanzo, A. Narcisi","doi":"10.23736/S0392-0488.20.06671-7","DOIUrl":"https://doi.org/10.23736/S0392-0488.20.06671-7","url":null,"abstract":"","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2020-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89283642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-16DOI: 10.23736/S0392-0488.20.06632-8
A. Virdi, A. Patrizi, S. Cambiaghi, A. Diociaiuti, M. El Hachem, D. Schena, A. Bassi, D. Bonamonte, V. Brazzelli, A. Belloni Fortina, P. Pepe, V. Di Lernia, I. Neri
BACKGROUND There are still few dermatological studies on morphea. We evaluated the epidemiological and clinical features and management of pediatric morphea, reporting dermatologists experience. METHODS A multicentre retrospective observational study was carried out on the epidemiological and clinical features and management of the disease between 01/01/2009 and 01/10/2014 in 10 Italian Dermatological Units. RESULTS We collected the data of 69 children affected by: circumscribed morphea (39.1%); linear morphea of trunk and limbs (14.5%); en coupe de sabre morphea (ECDS) (14.5%); progressive facial hemiatrophy (8.7%); generalized form (18.8%); mixed morphea (4.4%). The mean age at onset was 6.86±3.21 years, mainly between 2 and 8 years, but is statistically significantly lower for ECDS (4.5±3.03). Localizations were: head/neck (30.4%), limbs (26.1%), trunk (14.5%), 2 or more sites (29%), most often the trunk plus limbs. Extracutaneous manifestations were observed in 26.1% patients. 10 patients presented a second autoimmune disorder. Treatments were topical in 26.1% cases and systemic (alone or associated with topical treatments) in 68.1%. CONCLUSIONS There was a lack of uniformity in the management of patients and an increasing awareness of dermatologists on the use of systemic therapies, in particular of methotrexate, which is no longer exclusive to rheumatologists. Methotrexate causes stabilization and improvement of the clinical signs, but topical creams are still considered adjuvant or maintenance therapies during/after the use of systemic drugs.
{"title":"A retrospective study on clinical subtypes and management of morphea in 10 Italian Dermatological Units.","authors":"A. Virdi, A. Patrizi, S. Cambiaghi, A. Diociaiuti, M. El Hachem, D. Schena, A. Bassi, D. Bonamonte, V. Brazzelli, A. Belloni Fortina, P. Pepe, V. Di Lernia, I. Neri","doi":"10.23736/S0392-0488.20.06632-8","DOIUrl":"https://doi.org/10.23736/S0392-0488.20.06632-8","url":null,"abstract":"BACKGROUND\u0000There are still few dermatological studies on morphea. We evaluated the epidemiological and clinical features and management of pediatric morphea, reporting dermatologists experience.\u0000\u0000\u0000METHODS\u0000A multicentre retrospective observational study was carried out on the epidemiological and clinical features and management of the disease between 01/01/2009 and 01/10/2014 in 10 Italian Dermatological Units.\u0000\u0000\u0000RESULTS\u0000We collected the data of 69 children affected by: circumscribed morphea (39.1%); linear morphea of trunk and limbs (14.5%); en coupe de sabre morphea (ECDS) (14.5%); progressive facial hemiatrophy (8.7%); generalized form (18.8%); mixed morphea (4.4%). The mean age at onset was 6.86±3.21 years, mainly between 2 and 8 years, but is statistically significantly lower for ECDS (4.5±3.03). Localizations were: head/neck (30.4%), limbs (26.1%), trunk (14.5%), 2 or more sites (29%), most often the trunk plus limbs. Extracutaneous manifestations were observed in 26.1% patients. 10 patients presented a second autoimmune disorder. Treatments were topical in 26.1% cases and systemic (alone or associated with topical treatments) in 68.1%.\u0000\u0000\u0000CONCLUSIONS\u0000There was a lack of uniformity in the management of patients and an increasing awareness of dermatologists on the use of systemic therapies, in particular of methotrexate, which is no longer exclusive to rheumatologists. Methotrexate causes stabilization and improvement of the clinical signs, but topical creams are still considered adjuvant or maintenance therapies during/after the use of systemic drugs.","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2020-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75389848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-16DOI: 10.23736/S0392-0488.20.06649-3
V. Gaspari, Rossella Lacava, A. Barisani, C. Misciali, A. D’antuono, B. Raone, S. Vaccari
{"title":"Vegas xanthoma: a challenging diagnosis in dermatology.","authors":"V. Gaspari, Rossella Lacava, A. Barisani, C. Misciali, A. D’antuono, B. Raone, S. Vaccari","doi":"10.23736/S0392-0488.20.06649-3","DOIUrl":"https://doi.org/10.23736/S0392-0488.20.06649-3","url":null,"abstract":"","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2020-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78035507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-09DOI: 10.23736/S0392-0488.20.06621-3
Huotao Li, Jiao Zhang, Yongfeng Chen
{"title":"Methotrexate-induced toxic epidermal necrolysis in a child undergoing a combination therapy for systemic lupus erythematosus: a rare case report.","authors":"Huotao Li, Jiao Zhang, Yongfeng Chen","doi":"10.23736/S0392-0488.20.06621-3","DOIUrl":"https://doi.org/10.23736/S0392-0488.20.06621-3","url":null,"abstract":"","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72465886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-09DOI: 10.23736/S0392-0488.20.06623-7
A. Dattola, L. Vollono, M. V. Cannizzaro, R. D. Caposiena Caro, S. Mazzilli, G. Melino, E. Candi, E. Campione, L. Bianchi
BACKGROUND The efficacy and safety of Certolizumab Pegol over 52 weeks was compared in two groups of patients: Group 1 comprised patients naïve to biologic treatments; Group 2 comprised patients previously treated with one or more anti-Tumor necrosis factor (TNF)-alpha and/or antiinterleukin (IL) agents. METHODS We reported results in 50 patients affected by both mild psoriasis (PsO) and psoriatic arthritis (PsA). Primary endpoint was a reduction from baseline at week 52 of Disease Activity Score (DAS44-ESR) in both groups of patients. Secondary endpoints were a reduction from baseline at week 52 of Psoriasis Area Severity Index (PASI), Visual Analog Scale for Pain (PAIN VAS), ESR, CRP, and Dermatology life quality index (DLQI). RESULTS We observed a statistically significant improvement of both cutaneous and rheumatic disease in all patients, with a consistent reduction of DAS44-ESR, PASI, and PAIN VAS from baseline to week 52. DAS44-ESR decreased from 3.9 at BL to 1.5 at W52 (Group 1), and from 3.8 to 1.7 at W52 (Group 2). Mean PASI score decreased from 3.2 at baseline (BL) to 0.4 at W52 (Group 1), and from 5.4 to 0.7 at W52 (Group 2). Mean PAIN-VAS decreased from a value of 73.5 at BL to 2.5 at W52 (Group 1), and from a value of 62.4 at BL to 9.2 at W52 (Group 2). We also found a reduction in ESR, CRP and DLQI values for each time point. CONCLUSIONS Our results confirm that CZP can be administered safely and effectively to treat both psoriasis and psoriatic arthritis irrespective of previous treatments with biologic agents.
{"title":"Efficacy of Certolizumab Pegol in naïve versus multi-treated patients affected by psoriatic arthritis.","authors":"A. Dattola, L. Vollono, M. V. Cannizzaro, R. D. Caposiena Caro, S. Mazzilli, G. Melino, E. Candi, E. Campione, L. Bianchi","doi":"10.23736/S0392-0488.20.06623-7","DOIUrl":"https://doi.org/10.23736/S0392-0488.20.06623-7","url":null,"abstract":"BACKGROUND\u0000The efficacy and safety of Certolizumab Pegol over 52 weeks was compared in two groups of patients: Group 1 comprised patients naïve to biologic treatments; Group 2 comprised patients previously treated with one or more anti-Tumor necrosis factor (TNF)-alpha and/or antiinterleukin (IL) agents.\u0000\u0000\u0000METHODS\u0000We reported results in 50 patients affected by both mild psoriasis (PsO) and psoriatic arthritis (PsA). Primary endpoint was a reduction from baseline at week 52 of Disease Activity Score (DAS44-ESR) in both groups of patients. Secondary endpoints were a reduction from baseline at week 52 of Psoriasis Area Severity Index (PASI), Visual Analog Scale for Pain (PAIN VAS), ESR, CRP, and Dermatology life quality index (DLQI).\u0000\u0000\u0000RESULTS\u0000We observed a statistically significant improvement of both cutaneous and rheumatic disease in all patients, with a consistent reduction of DAS44-ESR, PASI, and PAIN VAS from baseline to week 52. DAS44-ESR decreased from 3.9 at BL to 1.5 at W52 (Group 1), and from 3.8 to 1.7 at W52 (Group 2). Mean PASI score decreased from 3.2 at baseline (BL) to 0.4 at W52 (Group 1), and from 5.4 to 0.7 at W52 (Group 2). Mean PAIN-VAS decreased from a value of 73.5 at BL to 2.5 at W52 (Group 1), and from a value of 62.4 at BL to 9.2 at W52 (Group 2). We also found a reduction in ESR, CRP and DLQI values for each time point.\u0000\u0000\u0000CONCLUSIONS\u0000Our results confirm that CZP can be administered safely and effectively to treat both psoriasis and psoriatic arthritis irrespective of previous treatments with biologic agents.","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78904226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-09DOI: 10.23736/S0392-0488.20.06619-5
B. Gualtieri, A. Marzano, S. Grando
In this review, we recap current knowledge about non-desmoglein autoantigens in atypical forms of autoimmune pemphigus. More than 50 keratinocyte proteins, including adhesion molecules, receptors and enzymes as well as mitochondrial proteins can be targeted, leading to alterations in numerous intracellular signaling pathways. Patients with pemphigus herpetiformis feature various combinations of antibodies to desmogleins 1 and 3 and desmocollins 1-3. Pemphigus vulgaris patients who do not have antibodies to desmogleins develop typical clinical and histological features of pemphigus. Experimental results revealed synergy of different autoantibodies. Alterations of the keratinocyte adhesive function caused by a single antibody alone are reversible due to self-repair. Since composition of the pool of the most common pathogenic antibodies appears to be similar among pemphigus patients with or without antidesmoglein antibodies, the atypical pemphigus represents a unique model for elucidation of the molecular mechanisms of autoimmunity against non-desmoglein antigens. Further studies of the immunopathology of atypical pemphigus should shed new lights on the pathophysiology of conventional variants of autoimmune pemphigus.
{"title":"Atypical pemphigus: autoimmunity against desmocollins and other non-desmoglein autoantigens.","authors":"B. Gualtieri, A. Marzano, S. Grando","doi":"10.23736/S0392-0488.20.06619-5","DOIUrl":"https://doi.org/10.23736/S0392-0488.20.06619-5","url":null,"abstract":"In this review, we recap current knowledge about non-desmoglein autoantigens in atypical forms of autoimmune pemphigus. More than 50 keratinocyte proteins, including adhesion molecules, receptors and enzymes as well as mitochondrial proteins can be targeted, leading to alterations in numerous intracellular signaling pathways. Patients with pemphigus herpetiformis feature various combinations of antibodies to desmogleins 1 and 3 and desmocollins 1-3. Pemphigus vulgaris patients who do not have antibodies to desmogleins develop typical clinical and histological features of pemphigus. Experimental results revealed synergy of different autoantibodies. Alterations of the keratinocyte adhesive function caused by a single antibody alone are reversible due to self-repair. Since composition of the pool of the most common pathogenic antibodies appears to be similar among pemphigus patients with or without antidesmoglein antibodies, the atypical pemphigus represents a unique model for elucidation of the molecular mechanisms of autoimmunity against non-desmoglein antigens. Further studies of the immunopathology of atypical pemphigus should shed new lights on the pathophysiology of conventional variants of autoimmune pemphigus.","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74569884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：